BioIntervene is a preclinical-stage biopharmaceutical company dedicated to the development of innovative and non-addictive medications for chronic pain, as well as other chronic inflammatory and neurodegenerative disorders. Established in 2014, BioIntervene emerged from groundbreaking research conducted at Saint Louis University and the National Institutes of Health (NIH). The company's founding team has been at the forefront of unraveling the intricacies of adenosine A 3 receptor biology and is specifically focused on creating groundbreaking, first-of-its-kind selective adenosine A 3 receptor agonists.

At BioIntervene, the primary goal is to tackle pain management and related disorders in a revolutionary manner. For inquiries, please reach out to info@biointervene. com.

© Copyright 2023 BioIntervene. All rights reserved. Website designed and constructed by Wildern